MERISTEM
DEAD

Serial Number

75407884

Owner

MERISTEM THERAPEUTICS

Attorney

John A. Clifford

Filing Date

Dec 18, 1997

Add to watchlist:

No watchlists yet
View on USPTO

MERISTEM Trademark

Serial Number: 75407884 • Registration: 2403115

MERISTEM is a trademark filed by MERISTEM THERAPEUTICS on December 18, 1997. The trademark is classified under Class 1 (Chemicals), Class 3 (Cosmetics & Cleaning), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

MERISTEM THERAPEUTICS (6 trademarks)

8 RUE DES FRERES LUMIERE
F-6300 CLERMONT-FERRAND , FR

Entity Type: 03

BIOCEM S.A. (2 trademarks)

24, avenue des Landais
63170 Aubiere , FR

Entity Type: 03

Trademark Details

Filing Date

December 18, 1997

Registration Date

November 14, 2000

Published for Opposition

March 28, 2000

Cancellation Date

June 17, 2011

Goods & Services

[ pharmaceutical preparations for use in the treatment of cystic fibrosis, obesity, emphysema, hemoglobin insufficiency, blood oxygen insufficiency, albumin insufficiency, collagen insufficiency, auto-immune diseases, namely, human immunodeficiency virus and multiple sclerosis, iron insufficiency and rabies; veterinary preparations for the treatment of rabies, obesity, auto-immune diseases, namely, feline immunodeficiency virus and simian immunodeficiency virus, in livestock, domestic pets and wild animals, namely, foxes and rodents; acaricides, algaccides, biopesticides, herbicides, insecticides, miticides, pesticides and weed killers for agricultural, domestic or commercial use; pharmaceutical preparations produced from plants or containing proteins produced from plants, for use in the treatment of cystic fibrosis, obesity, emphysema, hemoglobin insufficiency, blood oxygen insufficiency, albumin insufficiency, collagen insufficiency, auto-immune diseases, namely, human immunodeficiency virus and multiple sclerosis, iron insufficiency and rabies; therapeutic proteins, hormones, peptides and their complexes, derivatives and cofactors, namely, human serum albumin, lactoferrin, hemoglobin, collagen and procollagen for use in the treatment of cystic fibrosis, obesity, emphysema, hemoglobin insufficiency, blood oxygen insufficiency, albumin insufficiency, collagen insufficiency, auto-immune diseases, namely, immunodeficiency virus and multiple sclerosis, iron insufficiency and rabies; vaccines including antibodies or glycoproteins, namely, glycoprotein G, lipases, namely, gastric lipase, pancreatic lipase; and medicines and pharmaceutical preparations obtained from genetically modified plants or containing the extracts of genetically modified plants for use in the treatment of cystic fibrosis, obesity, emphysema, hemoglobin insufficiency, blood oxygen insufficiency, albumin insufficiency, collagen insufficiency, auto-immune diseases, namely, immunodeficiency virus and multiple sclerosis, iron insufficiency and rabies ]

[ Proteins for use as ingredients in skin lotions, oils and creams; for use as ingredients in sun tan lotions, oils and creams; for use as ingredients in skin hydrating lotions, oils and creams, namely, collagen, serum albumin, RNA, DNA and their extracts, amino acids, ribosomes, ceramides, immunostimulating or immunoregulatory hormones, all obtained from plants; and enzymes for use as ingredients in skin lotions, oils and creams; for use as ingredients in sun tan lotions, oils and creams; for use as ingredients in skin hydrating lotions, oils and creams, namely, proteases, hydrolases, lipases, deshydroxylases and cellulases, all obtained from plants ]

[ Chemicals for use in the manufacture of photographic materials, namely, dyes, wetting agents, fixing agents, developing agents, and stabilizers; chemicals for use in the manufacture of paints, dyes, cosmetics, glues and surfactants; chemicals for use in the manufacture of horticultural materials, namely, soil conditioners, fertilizers; chemicals for use in the manufacture of hormones, peptides, enzymes, and proteins, namely, plant and animal and microbial growth hormones, growth regulators and inhibitors, diagnostic reagents, cell growth media, cell regulatory agents, amino acids, DNA fragments, RNA fragments, DNA probes, RNA probes, genetic cloning materials, genetic expression amplifiers ]

Scientific and industrial research, namely biotechnological research on chemical products intended for industry, science, photography, agriculture, horticulture and forestry, on proteins for pharmaceutical use or for cosmetic use, these proteins being produced from plants, on pharmaceutical and veterinary products and hygiene products coming under the pharmaceutical monopoly, on biotechnological products produced from plants; biological and biotechnological laboratory services; research and development work in plant-based biotechnology

Filing History

CANCELLED SEC. 8 (10-YR)/EXPIRED SECTION 9
Jun 17, 2011 CAEX
REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED
Feb 1, 2008 8.PR
RESPONSE RECEIVED TO POST REG. ACTION - SEC. 8
Dec 17, 2007 PRA8
PAPER RECEIVED
Dec 17, 2007 MAIL
POST REGISTRATION ACTION MAILED - SEC. 8
Nov 7, 2007 PRA8
RESPONSE RECEIVED TO POST REG. ACTION - SEC. 8
Jul 26, 2007 PRA8
PAPER RECEIVED
Jul 26, 2007 MAIL
POST REGISTRATION ACTION MAILED - SEC. 8
Jun 14, 2007 PRA8
ASSIGNED TO PARALEGAL
Jun 7, 2007 PLGL
REGISTERED - SEC. 8 (6-YR) FILED
May 14, 2007 8.AF
TEAS SECTION 8 RECEIVED
May 14, 2007 ES8R
CASE FILE IN TICRS
Aug 10, 2006 CFIT
REGISTERED-PRINCIPAL REGISTER
Nov 14, 2000 R.PR
EXTENSION OF TIME TO OPPOSE RECEIVED
May 1, 2000 ETOF
PUBLISHED FOR OPPOSITION
Mar 28, 2000 PUBO
NOTICE OF PUBLICATION
Feb 25, 2000 NPUB
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 12, 1999 CNSA
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 7, 1999 CRFA
FINAL REFUSAL MAILED
Feb 25, 1999 CNFR
Sec. 1(B) CLAIM DELETED
Jan 26, 1999 1.BD
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 14, 1999 CRFA
NON-FINAL ACTION MAILED
Aug 31, 1998 CNRT
ASSIGNED TO EXAMINER
Aug 27, 1998 DOCK
ASSIGNED TO EXAMINER
Aug 18, 1998 DOCK